Related Experiment Video

Updated: Oct 25, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

787

Emerging roles of a pivotal lncRNA SBF2-AS1 in cancers

Qian Lu1, Jun Lou1, Ruyun Cai2

  • 1Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Cancer Cell International
|August 10, 2021
PubMed

Insights

SBF2-AS1, a long non-coding RNA (lncRNA), is highly expressed in many cancers and promotes tumor growth and spread. This lncRNA may serve as a diagnostic and prognostic biomarker for cancer patients.

Area of Science:

  • Molecular Biology
  • Genomics
  • Oncology

Background:

  • Long non-coding RNAs (lncRNAs) are crucial in human diseases, particularly cancers.
  • SBF2-AS1 is a newly identified lncRNA implicated in various cancer types.
  • Elevated SBF2-AS1 expression correlates with aggressive cancer characteristics and poor prognosis.

Purpose of the Study:

  • To review the current understanding of SBF2-AS1's mechanisms and functions in different cancers.
  • To highlight SBF2-AS1's potential as a biomarker and therapeutic target.

Main Methods:

  • Literature review of studies investigating SBF2-AS1 in cancer.
  • Analysis of SBF2-AS1 expression patterns, functional roles, and clinical significance.

Main Results:

  • SBF2-AS1 is upregulated across diverse cancer types.
  • SBF2-AS1 promotes tumorigenesis, progression, and metastasis.
  • Its expression is linked to adverse clinicopathologic features.

Conclusions:

  • SBF2-AS1 plays a significant role in cancer development and progression.
  • SBF2-AS1 holds promise as a diagnostic and prognostic biomarker.
  • Targeting SBF2-AS1 may offer a novel therapeutic strategy for cancer treatment.
Keywords:
BiomarkerCancersLncRNAMolecular mechanismSBF2-AS1Therapy target

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.0K
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
58.0K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.4K